Trial Profile
A Blinded, Placebo-Controlled, Dose-Escalation, Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 757456 Administered Subcutaneously to Healthy Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs IONIS AGT LRx (Primary)
- Indications Chronic heart failure; Hypertension
- Focus Adverse reactions
- Sponsors Ionis Pharmaceuticals
- 17 May 2021 Results of NCT03101878 and NCT03714776, presented at the 70th Annual Scientific Session of the American College of Cardiology.
- 20 Aug 2018 Status changed from active, no longer recruiting to completed.
- 01 May 2018 Planned End Date changed from 31 Jan 2019 to 31 Aug 2018.